For decades, liver disease carried a familiar stigma. It was linked to alcohol, to excess, to choices judged harshly and often whispered about rather than openly discussed. That narrative has now collapsed. Across the world, and increasingly across India, liver disease is no longer hiding in bars or bottles. It is sitting at dining tables, inside office chairs, beneath expanding waistlines, and within daily routines that feel ordinary, harmless, and deeply modern. Non-alcoholic fatty liver disease, now formally renamed metabolic dysfunction–associated steatotic liver disease, has emerged as the most common chronic liver disorder on the planet, affecting nearly one in three adults globally. In India, the numbers are rising fast, quietly, and with worrying speed.

The scale of this condition becomes clearer when one understands that MASLD is no longer a niche diagnosis found incidentally on ultrasound reports. It is a metabolic disease rooted in lifestyle, driven by abdominal obesity, insulin resistance, and chronic low-grade inflammation. A major international analysis published in the Journal of the American Medical Association confirms what clinicians have been sensing for years: excess fat around the waist is the single most powerful risk factor for fatty liver disease. The liver, an organ designed to process nutrients and detoxify the body, becomes overwhelmed when metabolic balance is lost. Fat begins to accumulate inside liver cells, and when it crosses a critical threshold, damage follows.

What makes MASLD particularly dangerous is how normal it feels at first. There is no pain, no early alarm, no dramatic symptom that forces a hospital visit. Many patients discover the disease during routine health checks, often after years of living with obesity, borderline diabetes, or high cholesterol. In India, where preventive health screenings remain limited and delayed, the disease often reveals itself late, when damage is already well underway. Estimates from the Union health ministry suggest that prevalence in the country may range anywhere from single digits to more than half the adult population, depending on region, urbanisation, and lifestyle patterns. Such a wide range reflects not uncertainty, but uneven detection.

This condition was once described as non-alcoholic fatty liver disease, a term that defined it by what it was not. The new name, metabolic dysfunction–associated steatotic liver disease, reflects a deeper understanding of its origins. This is a disease of modern metabolism. It sits at the crossroads of obesity, type 2 diabetes, hypertension, and abnormal lipid profiles. Nearly two-thirds of people with type 2 diabetes have MASLD. Among those living with obesity, the figure rises even higher. As waistlines expand, liver fat follows.

Indian doctors are increasingly alarmed by how early the disease appears. Men tend to develop MASLD at younger ages, often peaking in their late forties, while women show higher prevalence after menopause, when hormonal protection fades. Yet these patterns are shifting. Younger adults, driven by sedentary jobs, screen-heavy lifestyles, ultra-processed diets, and chronic sleep deprivation, are now presenting with fatty liver in their thirties. In some cases, even earlier.

The danger lies in the disease spectrum. At one end is simple fatty liver, where fat accumulation occurs without significant inflammation. At this stage, the condition is largely reversible. Weight loss, physical activity, and dietary correction can restore liver health. At the other end lies non-alcoholic steatohepatitis, where fat triggers inflammation and liver cell injury. If this inflammation persists, scarring begins. Fibrosis sets in, slowly stiffening the liver. Over time, advanced fibrosis can progress to cirrhosis, liver failure, and hepatocellular carcinoma. In India, up to 40 percent of liver cancer cases are now linked to fatty liver disease, a statistic that would have seemed improbable just two decades ago.

One of the most concerning findings of the global analysis is how central abdominal obesity is to disease risk. For Asian populations, the danger begins at lower thresholds than in Western counterparts. A body mass index above 23 significantly increases risk, compared with 25 in white populations. Waist circumference tells an even more important story. A waist measurement above 80 centimetres in women and 94 centimetres in men signals heightened metabolic risk. These numbers are now common in urban India, where prosperity has altered food choices faster than health awareness has adapted.

MASLD rarely travels alone. It marches alongside high blood pressure, elevated triglycerides, low levels of protective HDL cholesterol, and increasing reliance on lipid-lowering drugs. Each additional feature of metabolic syndrome compounds liver risk. The disease becomes more severe as these factors accumulate. It is this clustering that makes MASLD such a powerful predictor of future illness. It increases the risk of heart attacks, strokes, and certain cancers, even beyond the liver itself. In many patients, cardiovascular disease becomes a more immediate threat than liver failure.

Despite its rising prevalence, MASLD remains deeply misunderstood by the public. Many still believe liver disease requires alcohol abuse. Others assume that normal liver enzyme tests mean all is well. In reality, liver enzymes can remain deceptively normal even as fat and fibrosis advance. This false reassurance delays diagnosis and intervention. By the time enzymes rise or symptoms appear, damage may already be significant.

Treatment, for now, remains refreshingly simple and frustratingly difficult. Lifestyle change is the foundation of care. The JAMA analysis reinforces what hepatologists have long advocated: modest, sustained weight loss can dramatically improve liver fat and inflammation. A reduction of 7 to 10 percent of body weight is often enough to reverse early disease. Regular physical activity plays a crucial role. At least 150 minutes of moderate-intensity exercise per week, or 75 to 150 minutes of vigorous activity, can slow progression and, in many cases, restore liver health.

Diet matters deeply. Pro-inflammatory foods accelerate liver injury. Refined sugars, especially fructose, ultra-processed snacks, and saturated fats such as butter, ghee, lard, and coconut oil place additional strain on hepatic metabolism. In contrast, diets rich in vegetables, whole grains, lean proteins, and healthy fats support metabolic balance. Interestingly, unsweetened black coffee has emerged as a protective factor. European liver disease guidelines suggest that up to three cups a day may reduce the risk of disease progression and liver cancer among people with MASLD.

Alcohol avoidance remains essential. Even modest consumption can worsen liver injury in those with existing fat accumulation. This point often surprises patients who believe that “social drinking” is harmless. In the context of metabolic liver disease, there is no safe threshold.

Pharmacological options are beginning to appear, though they are far from miracle cures. Drugs such as resmetirom and semaglutide have received conditional approval from the US Food and Drug Administration for select patients with moderate to advanced disease. These medications target metabolic pathways and can reduce liver fat and inflammation. Yet experts caution strongly against viewing them as substitutes for lifestyle correction. Pills cannot undo years of metabolic imbalance if habits remain unchanged.

What complicates India’s response to MASLD is the broader context of urbanisation and inequality. Processed food is often cheaper and more accessible than fresh produce. Sedentary jobs dominate city life. Long commutes erode time for exercise. Cultural norms still equate weight gain with prosperity. Preventive healthcare remains a luxury for many. In rural areas, undernutrition and obesity now coexist, creating a double burden of disease.

The economic implications are significant. Advanced liver disease requires costly interventions, including hospitalisation, long-term medication, and in some cases, transplantation. India’s transplant infrastructure is already strained. Preventing disease progression is far more affordable than treating end-stage complications. Yet prevention demands sustained public health messaging, early screening, and a cultural shift in how lifestyle is valued.

MASLD also challenges the booming wellness industry. “Liver detox” products flood online marketplaces, promising quick fixes and cleansing cures. Hepatologists repeatedly warn that these products are unproven and often misleading. The liver does not need detoxification; it needs metabolic relief. Exercise, weight loss, and dietary balance achieve far more than any supplement ever could.

As India struggles with rising obesity and diabetes, MASLD stands as a mirror reflecting broader metabolic dysfunction. It is largely preventable, often reversible in its early stages, and deeply linked to choices made daily. Yet without awareness, it remains invisible. Without screening, it advances silently. Without lifestyle change, it progresses relentlessly.

The liver, resilient as it is, can only adapt so far. The expanding belly, once dismissed as a cosmetic issue, has become a clinical warning sign. In that curve of the waist lies a story of insulin resistance, inflammation, and future disease. Whether India chooses to read that story early, or confront it late, will shape the next decade of public health